Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Phase 3 Recruiting 450 enrolled Alexion Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Timeline

Start: 2025-05-19
Primary completion: 2027-11-30
Completion: 2028-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ravulizumab	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.